Advances in diagnosis and treatment of autosomal dominant polycystic kidney disease
10.11855/j.issn.0577-7402.2017.11.16
- VernacularTitle:常染色体显性遗传性多囊肾病的诊疗进展
- Author:
yuan Xiao WU
1
;
yuan Xue BAI
Author Information
1. 100853北京,解放军总医院肾脏病科、解放军肾脏病研究所、肾脏疾病国家重点实验室、国家慢性肾病临床医学研究中心、肾脏疾病研究北京市重点实验室
- Keywords:
autosomal dominant polycystic kidney disease;
diagnosis;
drug therapy
- From:
Medical Journal of Chinese People's Liberation Army
2017;42(11):1020-1024
- CountryChina
- Language:Chinese
-
Abstract:
Autosomal dominant polycystic kidney disease (ADPKD) is a common single-gene inherited kidney disease,and also the fourth leading cause of end-stage renal disease (ESRD).Currently,no effective treatment exists to delay ADPKD progression.In recent years,there has been great progress in gene research,diagnosis and treatment of ADPKD.Moreover,clinical trials were conducted using somatostatin analogs and vasopressin receptor antagonists,and resulted in the approval of tolvaptan in treatment of ADPKD in some countries.The relevant research status and developments of ADPKD will be summarized in the present paper focusing on the diagnosis and treatment of the disease.
